AVGR - アビンガ― （Avinger Inc.）

Avinger (AVGR) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close.The consensus EPS Estimate is -$0.49 and the consensus Revenue Estimate is $2M…

REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f…

REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, …

REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based syste…

REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England. The CX Symposium is a leading vascular and endovascular education conference focused on education, innovation, and evidence. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger''s Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Dr. Arne Schwindt, a vascular surgeon and endovascular interventionist in one of Germany''s leading endovascular centers at St. Franziskus Hospital in Münster, presented 6 and 12-month follow-up results in his presentation entitled "Treatment of In-stent Restenosis with an Atherectomy Catheter: Results from the INSIGHT Study." Data from the study supported the subsequent 510(k) clearance by the U.S.

Start Time: 16:30 End Time: 16:50 Avinger, Inc (NASDAQ:NASDAQ:AVGR) Q3 2022 Earnings Conference Call November 09, 2022, 16:30 PM ET Company Participants Jeff Soinski - CEO Nabeel Subainati…

Avinger press release (AVGR): Q3 GAAP EPS of -$0.77.Revenue of $2.25M (-5.1% Y/Y).Gross margin of 35%, with increased revenue and capital sales driving a 4-percentage point…

REDWOOD CITY, CA / ACCESSWIRE / November 4, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of seven new U.S. and international patents in the second and third quarters of 2022 and provided an update on the expansion of its intellectual property portfolio. The seven new patents expand intellectual property protection for Avinger''s proprietary image-guided atherectomy systems. In the second and third quarters of 2022, Avinger has been granted four (4) issued U.S. patents, two (2) issued European patents and one (1) issued Japanese patent, including: U.S. patent 11,399,863, Atherectomy Catheter with Serrated Cutter U.S. patent 11,344,327, Catheter Device with Detachable Distal End U.S. patent 11,406,412, Atherectomy Catheters with Imaging U.S. patent 11,382,653, Atherectomy Catheter . Avinger has increased its patent portfolio significantly in 2022, with 8 new patents issued or allowed in the U.S. and 8 new patents issued or allowed in international markets.

Gainers Avinger, Inc. (NASDAQ: AVGR ) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) shares rose 28.8% to $23.55 in pre-market trading. Arcturus reported collaboration with CSL to develop and commercialize self-amplifying mRNA vaccines. Code Chain New Continent Limited (NASDAQ: CCNC ) rose 23.2% to $0.1770 in pre-market trading after declining 7% on Tuesday. Baudax Bio, Inc. (NASDAQ: BXRX ) rose 20.3% to $0.2388 in pre-market trading. Chegg, Inc. (NYSE: CHGG ) rose 19.1% to $25.14 in pre-market trading after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates. Scopus BioPharma Inc. (NASDAQ: SCPS ) rose 19% to $0.2988 in pre-market trading. Match Group, Inc. (NASDAQ: MTCH ) shares rose 16.2% to $51.00 in pre-market trading after the company reported better-than-expected Q3 results.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Astonishing stocks: Verastem, Inc. (NASDAQ:VSTM 1.68%), Avinger, Inc. (NASDAQ:AVGR -0.71%) appeared first on Stocks Equity .

REDWOOD CITY, CA / ACCESSWIRE / April 29, 2022 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery …

Avinger (AVGR) stock climbed 11.2% premarket on Tuesday after the medical device maker announced the full commercial launch of its Lightbox 3 imaging console.AVGR conducted a…

Checkmate Pharmaceuticals CMPI +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal.Axsome Therapeutics (AXSM) +27%

REDWOOD CITY, CA / ACCESSWIRE / April 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of …

New York, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Atherectomy Devices Market Size is Anticipated to Progress at a Significant CAGR of 9.24% During the Study Period, Assesses DelveInsight The Atherectomy Devices market size is expected to boost due to several factors such as rising geriatric population, rising prevalence of cardiovascular diseases, growing prevalence of lifestyle disorders such as hypertension and diabetes, and innovation in product development, among others. DelveInsight''s Atherectomy Devices Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Atherectomy Devices companies in the market. Key Takeaways from the Atherectomy Devices Market Report According to DelveInsight analysis, North America is anticipated to dominate the global Atherectomy Devices market during the forecast period. The leading Atherectomy Devices companies with various types of Atherectomy Devices in various stages of development such as Koninklijke Philips N.V., Medtronic, Boston Scientific Corporation, AngioDynamics Inc, Cardiovascular Systems Inc, Avinger, BD, Ra Medical Systems, REX Medical , and others are currently working in the Atherectomy Devices market.